Clinical trial · Observational
Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study
High-dose Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study
NCT01816503CI-TRIAL-00009797completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to show the clinical usefulness of fentanyl matrix by measuring satisfaction with pain treatment after administering fentanyl matrix in patients whose pain was not controlled sufficiently with the previous analgesic use in real practice at the investigator's discretion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Fentanyl matrix
- interventionNames
- Drug: No intervention
Primary outcomes (1)
- measure
- The percentage of patients who are very satisfied or satisfied with the pain treatment after the study drug administration
- timeFrame
- Day 10
- description
- The overall satisfaction is measured by a 5-point scale. Patients' answers are rated as: "very satisfied", "satisfied", "fair", "dissatisfied", or "very dissatisfied".
Secondary outcomes (8)
- measure
- The change from baseline in pain intensity
- timeFrame
- Baseline, up to Day 10
- description
- The mean pain intensity the patient experienced over the last 24 hours will be measured through Numeric Rating Scale (NRS); 0 = no pain, 10 = worst pain imaginable.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients complaining of cancer pain which requires administration of long-acting opioid analgesics * Patients whose pain is not sufficiently controlled despite administration of strong long-acting opioid analgesics * Patients who are deemed to need an initial minimum dose of fentanyl matrix 75 micrograms/h * Patients who signed the informed consent form Exclusion Criteria: * Patients with a history of or current drug or alcohol abuse * Childbearing women who are pregnant or likely to be pregnant during the study period and men who are neither infertile nor willing to refrain from sexual relations but whose partner does not conduct an effective contraception * Patients who are unable to use a transdermal system due to skin disease * Patients with history of hypersensitivity to opioid analgesics * Patients who are not eligible for the study participation based on warnings, precautions and contraindications in the package insert of the study drug at the investigator's discretion
References
Publications (0)
Data not yet available
No reference posted for this study.